GuidelineInternational journal of clinical practice2009
Practical guidance on intensification of insulin therapy with BIAsp 30: a consensus statement.
Guideline in International journal of clinical practice, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Subject-driven titration of biphasic insulin aspart 30 twice daily is non-inferior to investigator-driven titration in Chinese patients with type 2 diabetes inadequately controlled with premixed human insulin: A randomized, open-label, parallel-group, multicenter trial.Journal of diabetes investigation · 2016Trial
- Expert Opinion: Patient Selection for Premixed Insulin Formulations in Diabetes Care.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2018Review
- EADSG Guidelines: Insulin Therapy in Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2018Article
- Use of 50/50 Premixed Insulin Analogs in Type 2 Diabetes: Systematic Review and Clinical Recommendations.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2017Review
- Practical Guidance on the Use of Premix Insulin Analogs in Initiating, Intensifying, or Switching Insulin Regimens in Type 2 Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2015Article
- Management of diabetes mellitus type-2 in the geriatric population: Current perspectives.Journal of pharmacy & bioallied sciences · 2014Review
- Safety and Effectiveness of Switching from a Basal-only to Biphasic Insulin Aspart 30 Insulin Regimen.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2013Article
- Letter: efficacy and safety of biphasic insulin aspart 30/70 in type 2 diabetes suboptimally controlled on oral antidiabetic therapy in Korea: a multicenter, open-label, single-arm study (diabetes metab j 2013;37:117-24).Diabetes & metabolism journal · 2013Article
- Review
- Choice of long-acting insulin therapy for type 2 diabetes: how can treatment for older people be optimized?Drugs & aging · 2011Article
- Intensifying existing premix therapy (BIAsp 30) with BIAsp 50 and BIAsp 70: A consensus statement.Indian journal of endocrinology and metabolism · 2011Article
- Management of hyperglycemia in geriatric patients with diabetes mellitus: South Asian consensus guidelines.Indian journal of endocrinology and metabolism · 2011Article
- A commentary on the "consensus statement" regarding the use of BIAsp30.Journal of diabetes investigation · 2010Article
- An Audit of Insulin Usage and Insulin Injection Practices in a Large Indian Cohort.Indian journal of endocrinology and metabolismArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBasal insulin and premix insulin are commonly prescribed first-line insulin therapies for patients failing to maintain glycaemic control on oral therapy. When control on these insulins starts to drift, premix analogues, such as biphasic insulin aspart 30/70 (BIAsp 30), are a simple and effective tool for intensification as they can be injected up to three-times daily (TID). However, at present, international recommendations for intensification of insulin therapy using premix analogues are limited and specific guidance on dosing is not available for many scenarios.
methodsIn October 2008, an international expert panel met to review the current guidelines for insulin intensification with BIAsp 30 in patients with type 2 diabetes, with the aim of developing practical guidance for general and specialist practitioners.
resultsSimple treatment algorithms have been developed for (i) patients on basal insulin (human or analogue) once daily or twice daily (BID) who need intensification to BIAsp 30 BID, and (ii) patients on BIAsp 30 once daily or BID who can be intensified to BIAsp 30 BID or TID. As well as these algorithms, specific guidance has been provided on dose transfer (from basal insulin to BIAsp 30), dose split (when intensifying from once daily to BID), and combination oral therapies. In addition, a guide to dose titration is included.
conclusionsThe guidelines presented here should enable general or specialist practitioners to use BIAsp 30 to intensify the insulin therapy of patients failing on basal insulin or BIAsp 30 once or twice daily.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.